Skip to main content
Erschienen in: Annals of Surgical Oncology 5/2016

04.01.2016 | Gastrointestinal Oncology

Perioperative Treatment, Not Surgical Approach, Influences Overall Survival in Patients with Gastroesophageal Junction Tumors: A Nationwide, Population-Based Study in The Netherlands

verfasst von: Marijn Koëter, MD, Kevin Parry, MD, Rob H. A. Verhoeven, PhD, Misha D. P. Luyer, MD, PhD, Jelle P. Ruurda, MD, PhD, Richard van Hillegersberg, MD, PhD, Valery E. P. P. Lemmens, PhD, Grard A. P. Nieuwenhuijzen, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Resectable gastroesophageal junction (GEJ) tumors are treated either with an esophageal-cardia resection or with gastrectomy. The difference in outcome between these two treatment modalities is unknown; Therefore, the aim of this study was to evaluate population-based treatment strategies for patients with resectable adenocarcinomas of the GEJ and to compare the oncological outcomes.

Methods

Patients with potentially resectable GEJ tumors diagnosed between 2005 and 2012 were selected from the nationwide, population-based Netherlands Cancer Registry. Differences between patients were compared using the χ 2 test, and survival curves were generated using the Kaplan–Meier method. Overall multivariate survival was assessed using Cox regression analyses.

Results

Patients treated with esophagectomy (n = 939) were significantly younger than patients treated with gastrectomy (n = 257; 64 vs. 66 years; p < 0.001), and no differences were noted regarding lymph node yield, lymph node ratio, and radicality. Patients treated with an esophagectomy or gastrectomy exhibited comparable overall 5-year survival rates (36 vs. 33 %, respectively; p = 0.250). Multivariate analysis showed that patients receiving perioperative treatment and gastrectomy exhibited similar overall survival rates compared with patients receiving perioperative treatment and esophagectomy [hazard ratio (HR) 1.9, 95 % confidence interval (CI) 0.7–1.3; p = 0.908]; however, patients receiving esophagectomy alone (HR 1.3, 95 % CI 1.3–1.8; p = 0.002) or gastrectomy alone (HR 1.8, 95 % CI 1.4–2.4; p < 0.001) exhibited a significantly worse overall survival.

Conclusions

The chosen type of surgery (esophagectomy or gastrectomy) did not influence the overall survival in our cohort of patients with GEJ tumors. The administration of perioperative chemo(radio)therapy improved survival regardless of the surgical approach.
Literatur
1.
Zurück zum Zitat Dikken JL, Lemmens VE, Wouters MW, Wijnhoven BP, Siersema PD, Nieuwenhuijzen GA, et al. Increased incidence and survival for esophageal cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer. 2012;48(11):1624–32.CrossRefPubMed Dikken JL, Lemmens VE, Wouters MW, Wijnhoven BP, Siersema PD, Nieuwenhuijzen GA, et al. Increased incidence and survival for esophageal cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer. 2012;48(11):1624–32.CrossRefPubMed
2.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917.CrossRefPubMed Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917.CrossRefPubMed
3.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–249.CrossRefPubMed Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–249.CrossRefPubMed
4.
Zurück zum Zitat Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer. 2001;92(3):549–555.CrossRefPubMed Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer. 2001;92(3):549–555.CrossRefPubMed
5.
Zurück zum Zitat Siewert JR, Stein HJ. Classification of adenocarcinoma of the esophagogastric junction. Br J Surg. 1998;85(11):1457–1459.CrossRefPubMed Siewert JR, Stein HJ. Classification of adenocarcinoma of the esophagogastric junction. Br J Surg. 1998;85(11):1457–1459.CrossRefPubMed
6.
Zurück zum Zitat Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474.CrossRefPubMed Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474.CrossRefPubMed
7.
Zurück zum Zitat Haverkamp L, Ruurda JP, Van Leeuwen MS, Siersema PD, van Hillegersberg R. Systematic review of the surgical strategies of adenocarcinomas of the gastresophageal junction. Surg Oncol. 2014;23(4):222–228.CrossRefPubMed Haverkamp L, Ruurda JP, Van Leeuwen MS, Siersema PD, van Hillegersberg R. Systematic review of the surgical strategies of adenocarcinomas of the gastresophageal junction. Surg Oncol. 2014;23(4):222–228.CrossRefPubMed
8.
Zurück zum Zitat Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology, third edition. Geneva: World Health Organisation; 2000. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology, third edition. Geneva: World Health Organisation; 2000.
9.
Zurück zum Zitat Union for International Cancer Control. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002. Union for International Cancer Control. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002.
10.
Zurück zum Zitat Union for International Cancer Control. TNM classification of malignant tumors. 7th ed. New York: Wiley-Liss; 2009. Union for International Cancer Control. TNM classification of malignant tumors. 7th ed. New York: Wiley-Liss; 2009.
11.
Zurück zum Zitat Grotenhuis BA, Wijnhoven BP, Poley JW, Hermans JJ, Biermann K, Spaander MC, et al. Preoperative assessment of tumor location and station-specific lymph node status in patients with adenocarcinoma of the gastresophageal junction. World J Surg. 2013;37(1):147–155.CrossRefPubMed Grotenhuis BA, Wijnhoven BP, Poley JW, Hermans JJ, Biermann K, Spaander MC, et al. Preoperative assessment of tumor location and station-specific lymph node status in patients with adenocarcinoma of the gastresophageal junction. World J Surg. 2013;37(1):147–155.CrossRefPubMed
12.
Zurück zum Zitat Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, et al. Adenocarcinoma of the gastresophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg. 2007;246(1):1–8.CrossRefPubMedPubMedCentral Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, et al. Adenocarcinoma of the gastresophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg. 2007;246(1):1–8.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Johansson J, Djerf P, Oberg S, Zilling T, von Holstein CS, Johnsson F, et al. Two different surgical approaches in the treatment of adenocarcinoma at the gastresophageal junction. World J Surg. 2008;32(6):1013–1020.CrossRefPubMed Johansson J, Djerf P, Oberg S, Zilling T, von Holstein CS, Johnsson F, et al. Two different surgical approaches in the treatment of adenocarcinoma at the gastresophageal junction. World J Surg. 2008;32(6):1013–1020.CrossRefPubMed
14.
Zurück zum Zitat Reeh M, Mina S, Bockhorn M, Kutup A, Nentwich MF, Marx A, et al. Staging and outcome depending on surgical treatment in adenocarcinomas of the esophagogastric junction. Br J Surg. 2012;99(10):1406–1414.CrossRefPubMed Reeh M, Mina S, Bockhorn M, Kutup A, Nentwich MF, Marx A, et al. Staging and outcome depending on surgical treatment in adenocarcinomas of the esophagogastric junction. Br J Surg. 2012;99(10):1406–1414.CrossRefPubMed
15.
Zurück zum Zitat Ito H, Clancy TE, Osteen RT, Swanson RS, Bueno R, Sugarbaker DJ, et al. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? J Am Coll Surg. 2004;199(6):880–886.CrossRefPubMed Ito H, Clancy TE, Osteen RT, Swanson RS, Bueno R, Sugarbaker DJ, et al. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? J Am Coll Surg. 2004;199(6):880–886.CrossRefPubMed
16.
Zurück zum Zitat Mariette C, Castel B, Toursel H, Fabre S, Balon JM, Triboulet JP. Surgical management of and long-term survival after adenocarcinoma of the cardia. Br J Surg. 2002;89(9):1156–1163.CrossRefPubMed Mariette C, Castel B, Toursel H, Fabre S, Balon JM, Triboulet JP. Surgical management of and long-term survival after adenocarcinoma of the cardia. Br J Surg. 2002;89(9):1156–1163.CrossRefPubMed
17.
Zurück zum Zitat Parry K, Haverkamp L, Bruijnen RC, Siersema PD, Ruurda JP, van Hillegersberg R. Surgical Treatment of Adenocarcinomas of the Gastro-esophageal Junction. Ann Surg Oncol. 2015;22(2):597–603.CrossRefPubMed Parry K, Haverkamp L, Bruijnen RC, Siersema PD, Ruurda JP, van Hillegersberg R. Surgical Treatment of Adenocarcinomas of the Gastro-esophageal Junction. Ann Surg Oncol. 2015;22(2):597–603.CrossRefPubMed
18.
Zurück zum Zitat Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophago-gastric junction. Scand J Surg. 2006;95(4):260–269.PubMed Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophago-gastric junction. Scand J Surg. 2006;95(4):260–269.PubMed
19.
Zurück zum Zitat Martin JT, Mahan A, Zwischenberger JB, McGrath PC, Tzeng CW. Should gastric cardia cancers be treated with esophagectomy or total gastrectomy? A comprehensive analysis of 4,996 NSQIP/SEER patients. J Am Coll Surg. 2015;220(4):510–20.CrossRefPubMed Martin JT, Mahan A, Zwischenberger JB, McGrath PC, Tzeng CW. Should gastric cardia cancers be treated with esophagectomy or total gastrectomy? A comprehensive analysis of 4,996 NSQIP/SEER patients. J Am Coll Surg. 2015;220(4):510–20.CrossRefPubMed
20.
Zurück zum Zitat Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg. 2011;254(2):274–280.CrossRefPubMed Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg. 2011;254(2):274–280.CrossRefPubMed
21.
Zurück zum Zitat Koen TA, Shapiro J, Looman CW, van Hagen P, Steyerberg EW, van der Gaast A, et al. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg. 2014;260(5):786–792.CrossRef Koen TA, Shapiro J, Looman CW, van Hagen P, Steyerberg EW, van der Gaast A, et al. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg. 2014;260(5):786–792.CrossRef
22.
Zurück zum Zitat van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–2084.CrossRefPubMed van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–2084.CrossRefPubMed
23.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastresophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMed Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastresophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMed
24.
Zurück zum Zitat Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–692.CrossRefPubMed Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–692.CrossRefPubMed
25.
Zurück zum Zitat Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–856.CrossRefPubMed Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–856.CrossRefPubMed
26.
Zurück zum Zitat Burmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the esophagus? A randomised phase II trial. Eur J Cancer. 2011;47(3):354–360.CrossRefPubMed Burmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the esophagus? A randomised phase II trial. Eur J Cancer. 2011;47(3):354–360.CrossRefPubMed
27.
Zurück zum Zitat Dikken JL, van Sandick JW, Allum WH, Johansson J, Jensen LS, Putter H, et al. Differences in outcomes of esophageal and gastric cancer surgery across Europe. Br J Surg. 2013;100(1):83–94.CrossRefPubMed Dikken JL, van Sandick JW, Allum WH, Johansson J, Jensen LS, Putter H, et al. Differences in outcomes of esophageal and gastric cancer surgery across Europe. Br J Surg. 2013;100(1):83–94.CrossRefPubMed
28.
Zurück zum Zitat Barbour AP, Lagergren P, Hughes R, Alderson D, Barham CP, Blazeby JM. Health-related quality of life among patients with adenocarcinoma of the gastro-esophageal junction treated by gastrectomy or esophagectomy. Br J Surg. 2008;95(1):80–84.CrossRefPubMed Barbour AP, Lagergren P, Hughes R, Alderson D, Barham CP, Blazeby JM. Health-related quality of life among patients with adenocarcinoma of the gastro-esophageal junction treated by gastrectomy or esophagectomy. Br J Surg. 2008;95(1):80–84.CrossRefPubMed
29.
Zurück zum Zitat Spector NM, Hicks FD, Pickleman J. Quality of life and symptoms after surgery for gastresophageal cancer: a pilot study. Gastroenterol Nurs. 2002;25(3):120–125.CrossRefPubMed Spector NM, Hicks FD, Pickleman J. Quality of life and symptoms after surgery for gastresophageal cancer: a pilot study. Gastroenterol Nurs. 2002;25(3):120–125.CrossRefPubMed
Metadaten
Titel
Perioperative Treatment, Not Surgical Approach, Influences Overall Survival in Patients with Gastroesophageal Junction Tumors: A Nationwide, Population-Based Study in The Netherlands
verfasst von
Marijn Koëter, MD
Kevin Parry, MD
Rob H. A. Verhoeven, PhD
Misha D. P. Luyer, MD, PhD
Jelle P. Ruurda, MD, PhD
Richard van Hillegersberg, MD, PhD
Valery E. P. P. Lemmens, PhD
Grard A. P. Nieuwenhuijzen, MD, PhD
Publikationsdatum
04.01.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 5/2016
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-5061-7

Weitere Artikel der Ausgabe 5/2016

Annals of Surgical Oncology 5/2016 Zur Ausgabe

Regional Therapies for Advanced Malignancies

Regional Therapies for Advanced Cancer: Update for 2016

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.